Spots Global Cancer Trial Database for apx005m
Every month we try and update this database with for apx005m cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| APX005M and Doxorubicin in Advanced Sarcoma | NCT03719430 | Soft Tissue Sar... | Doxorubicin APX005M | 18 Years - | Columbia University | |
| APX005M and Doxorubicin in Advanced Sarcoma | NCT03719430 | Soft Tissue Sar... | Doxorubicin APX005M | 18 Years - | Columbia University | |
| APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | NCT03502330 | Advanced Melano... Non-small Cell ... Renal Cell Carc... | APX005M Cabiralizumab Nivolumab | 18 Years - | Yale University | |
| CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | NCT03123783 | Cancer Non Small Cell ... Metastatic Mela... Neoplasm of Lun... Melanoma | APX005M Nivolumab | 18 Years - | Apexigen America, Inc. | |
| APX005M in Patients With Recurrent Ovarian Cancer | NCT05201001 | Ovarian Cancer | APX005M | 18 Years - | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | NCT03123783 | Cancer Non Small Cell ... Metastatic Mela... Neoplasm of Lun... Melanoma | APX005M Nivolumab | 18 Years - | Apexigen America, Inc. | |
| APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | NCT03165994 | Esophageal Canc... GastroEsophagea... | APX005M Radiation Thera... Paclitaxel Carboplatin Surgical resect... | 18 Years - | Apexigen America, Inc. | |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | NCT03597282 | Metastatic Mela... | NEO-PV-01 Nivolumab Adjuvant APX005M ipilimumab | 18 Years - | BioNTech SE | |
| APX005M in Patients With Recurrent Ovarian Cancer | NCT05201001 | Ovarian Cancer | APX005M | 18 Years - | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | NCT04495257 | Advanced Melano... Renal Cell Carc... | Nivolumab Ipilimumab APX005M | 18 Years - | Yale University | |
| A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | NCT04495257 | Advanced Melano... Renal Cell Carc... | Nivolumab Ipilimumab APX005M | 18 Years - | Yale University | |
| Switch Maintenance in Pancreatic | NCT05419479 | Pancreatic Canc... Adenocarcinoma ... Squamous Cell C... Adenosquamous C... | ZIMBERELIMAB DOMVANALIMAB APX005M FOLFIRI | 18 Years - | Dana-Farber Cancer Institute | |
| APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma | NCT02706353 | Melanoma | APX005M Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma | NCT04337931 | Unresectable Me... Metastatic Mela... Cancer Cancer of Skin Melanoma Melanoma (Skin) | sotigalimab | 18 Years - | Apexigen America, Inc. | |
| Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | NCT03214250 | Metastatic Panc... | APX005M Nivolumab Nab-Paclitaxel Gemcitabine | 18 Years - | Parker Institute for Cancer Immunotherapy | |
| APX005M in Patients With Recurrent Ovarian Cancer | NCT05201001 | Ovarian Cancer | APX005M | 18 Years - | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | NCT03214250 | Metastatic Panc... | APX005M Nivolumab Nab-Paclitaxel Gemcitabine | 18 Years - | Parker Institute for Cancer Immunotherapy |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
